Company
Senior Executive Officers
Board of Directors
Ethics Advisory Board
Careers
Glossary
Contact Us
Technology
Regenerative Medicine
Blastomere Program
Cellular Reprogramming
Stem Cell Differentiation
Intellectual Property
Pipeline
Overview
Potential Markets
Myoblast Program
RPE Program
Hemangioblast (HG) Cell Program
News and Media
ACT Corporate Overview
Press Releases
Conference Presentations
Media Gallery
Media Contact
Safe Medication from Canadian Pharmacies
Investors
Investors Overview
Research Reports
Corporate Governance
Committee Charters
Whistleblower Hotline
Sitemap
Page 3 of 5 :
Previous
:
Next
Posts
Category:
Uncategorized
Regenerative Medicine - Innovative Approach to Health
Pages
2014 Biotech Showcase Presentation: january-13-2014
ACT Corporate Overview
ACT Corporate Presentation Bio CEO feb-2013
ACT Corporate Presentation BioCEO: february-2014
ACT Corporate Presentation: may-2013
ACT's Blastomere Technology
ACT's Investor and Stem Cell Conference Presentations
ACT's Phase 1/2 Program for Retinal Degeneration
ACT's Stem Cell-Related Research Pipeline
Advanced Cell Technology
Advanced Cell Technology
Hemangioblast (HG) Program
Intellectual Property
Pipeline
Pipeline of Therapeutic Programs
Regenerative Medicine
Technology: Blastomere Program
Advanced Cell Technology
Advanced Cell Technology Achieves Reversal of Cell Aging Science Journal Article Describes Milestone in Medical Research
ADVANCED CELL TECHNOLOGY ANNOUNCES BIRTH OF FIRST CLONED ENDANGERED SPECIES
Advanced Cell Technology Announces Technique to Generate Human Embryonic Stem Cells that Maintains Developmental Potential of Embryo
Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
All SEC Filings
Autologous Regenerative Medicine
Biographies
Blastomere Program
Board of Directors
Careers
CAuSMIC Trial CAuSMIC Trial
Cellular Reprogramming
Cima Biotechnology, Inc.
Cloning in Plants And Animals
Cloning Will Bring Back Endangered Animal Species
Committee Charters
Company Overview
Contact Us
Corporate Governance
Corporate Profile
Current Animal Cloning Program
Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells
Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients
Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease
Embryonic Stem Cell Trials for Macular Degeneration
Embryonic Stem Cells to Treat Age-Related Macular Degeneration
Embryonic Stem Cells/induced Pluripotent Stem Cells
Endangered Species Cloning
Endangered Species Cloning
Erythropoietin - Functional Red Blood Cells From Human Embryonic Stem Cells